{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:50:28Z","timestamp":1782211828443,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.prro.2025.12.014","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:11:39Z","timestamp":1768583499000},"page":"394-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Management of Locally Advanced Endometrial Cancer"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-144X","authenticated-orcid":false,"given":"Mary","family":"McGunigal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Sherertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idalid","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Portelance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu Prasad","family":"Venkatesulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareena","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"William","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Suneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Jhingran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.12.014_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2025.12.014_bib0002","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.14420","article-title":"Adjuvant chemoradiotherapy versus chemotherapy or radiotherapy in advanced endometrial cancer: A systematic review and meta-analysis","volume":"10","author":"Winarto","year":"2022","journal-title":"PeerJ"},{"key":"10.1016\/j.prro.2025.12.014_bib0003","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1002\/cncr.26030","article-title":"Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes?","volume":"117","author":"Cooke","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2025.12.014_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.prro.2025.12.014_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study","volume":"373","author":"Kitchener","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.12.014_bib0006","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006250-200211000-00041","article-title":"Postoperative neuropathies after major pelvic surgery","volume":"100","author":"Cardosi","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.prro.2025.12.014_bib0007","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ygyno.2006.03.055","article-title":"The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer Center","volume":"103","author":"Abu-Rustum","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study","volume":"24","author":"Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0009","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0010","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.12.014_bib0011","article-title":"Long-term follow-up and overall survival in NRG258, a randomized phase III trial of chemoradiation versus chemotherapy for locally advanced endometrial carcinoma","author":"Matei","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2012.10.010","article-title":"A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer","volume":"128","author":"Secord","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0013","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0360-3016(01)01566-8","article-title":"Significant pelvic recurrence in high-risk pathologic stage I\u2013IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy","volume":"50","author":"Mundt","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.014_bib0014","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.prro.2025.12.014_bib0015","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer\u2013results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2025.12.014_bib0016","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2006.02.007","article-title":"Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer","volume":"103","author":"Greven","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0018","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): Patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2010.12.338","article-title":"A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a \"Sandwich\" method for stage III, IV, and recurrent endometrial cancer","volume":"121","author":"Geller","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2023.11.012","volume":"180","author":"Barlin","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0021","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ygyno.2008.11.014","article-title":"A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study","volume":"112","author":"Homesley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0022","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2017.10.037","article-title":"An NRG Oncology\/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer","volume":"148","author":"Cosgrove","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0023","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.prro.2025.12.014_bib0024","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant Therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2025.01.006","article-title":"Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258","volume":"193","author":"Clements","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0026","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.prro.2025.12.014_bib0027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2018.07.020","article-title":"Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial","volume":"151","author":"Wortman","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0028","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.12.014_bib0029","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.12.014_bib0030","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0031","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1186\/s12885-023-11654-z","article-title":"PD-1\/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: A systematic review and meta-analysis of randomized clinical trials","volume":"23","author":"de Moraes","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2025.12.014_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102701","article-title":"Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis","volume":"125","author":"Bartoletti","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.prro.2025.12.014_bib0033","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/1471-0528.17749","article-title":"Immune checkpoint inhibitors plus chemotherapy in first-line endometrial cancer treatment: Still the era of microsatellites?","volume":"131","author":"Maiorano","year":"2024","journal-title":"Bjog"},{"key":"10.1016\/j.prro.2025.12.014_bib0034","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0035","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ijrobp.2012.02.044","article-title":"A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: Radiation therapy oncology group trial 0418","volume":"84","author":"Jhingran","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.014_bib0036","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2014.01.018","article-title":"Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: Results of the phase II RTCMIENDOMETRE French multicentre trial","volume":"111","author":"Barillot","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0037","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.19.02381","article-title":"Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: A report from the NRG oncology RTOG 1203 study","volume":"38","author":"Yeung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.12.014_bib0038","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijrobp.2020.08.061","article-title":"NRG Oncology\/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer: An update","volume":"109","author":"Small","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.014_bib0039","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijrobp.2010.08.024","article-title":"Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy","volume":"82","author":"Jhingran","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.12.014_bib0040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ijrobp.2007.09.042","article-title":"Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer","volume":"71","author":"Small","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:34:16Z","timestamp":1782210856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850026000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1879850026000044"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.12.014","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Management of Locally Advanced Endometrial Cancer","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}